Efonidipine

Catalog No.S4977 Batch:S497702

Technical Data

Formula

C₃₄H₃₈N₃O₇P

Molecular Weight

631.66

CAS No.

111011-63-3

Solubility (25°C)*

In vitro

DMSO

100 mg/mL (158.31 mM)

Ethanol

6 mg/mL (9.49 mM)

Water

Insoluble

In Vivo (Add solvents to the product individually and in order.)

Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (7.92mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Efonidipine (NZ-105) is an L- and T-type calcium channel blocker leading to vasodilation and decreased automaticity of the heart. It also suppresses aldosterone secretion from the adrenal.

Targets

T-type calcium channel

In vitro

Although efonidipine is not a specific T-type calcium channel (TTCC) blocker as it could also block L-type calcium channel (LTCC), its efficacy in blocking TTCC is much greater than that of LTCC. This compound exerts an inhibitory effect on aldosterone synthesis and secretion in a human adrenocortical cell line (H295R), an effect that is mediated, at least in part, by suppression of 11-β-hydroxylase and aldosterone synthase expression. It also suppresses both Ang II- and K+-induced aldosterone secretion, but it blocks the latter at much lower concentrations than the former.

In Vivo

Efonidipine could provide broader beneficial effects including the heart, liver, and plasma, and antioxidant in iron-overload condition in both WT(muβ^+⁄+) and HT(muβ^{th-3 ⁄+},) mice

Protocol (from reference)

Cell Assay:^{^[2]}	Cell Lines The NCI-H295R human adrenocortical cell line (H295) Concentrations 0.3 μM and 3 μM Incubation Time 24 h Method H295R cells are plated to a density of 0.2 × 10⁶ in 6-well plates and incubated for 48 hours, after which the medium is replaced with low-serum medium containing 0.2% UltroserSF, and the cells are then treated with Ang II (100 nmol/L) or KCl (10 mmol/L) with or without the indicated concentration of this compound for 24 hours. The cells are then harvested, and the total cellular RNA is extracted using the isothiocyanate-acid phenol chloroform method. After quantifying the extracted RNA based on absorbance at 260 nm, 500-ng aliquots are reverse transcribed.
Animal Study:^{^[1]}	Animal Models adult C57/BL6 mice (3-6 months old, heterozygous β^KO type) with FE diet (0.2% ferrocene w⁄w) Dosages 4 mg⁄kg Administration i.p.

Cell Assay:^{^[2]}

Cell Lines
The NCI-H295R human adrenocortical cell line (H295)
Concentrations
0.3 μM and 3 μM
Incubation Time
24 h
Method
H295R cells are plated to a density of 0.2 × 10⁶ in 6-well plates and incubated for 48 hours, after which the medium is replaced with low-serum medium containing 0.2% UltroserSF, and the cells are then treated with Ang II (100 nmol/L) or KCl (10 mmol/L) with or without the indicated concentration of this compound for 24 hours. The cells are then harvested, and the total cellular RNA is extracted using the isothiocyanate-acid phenol chloroform method. After quantifying the extracted RNA based on absorbance at 260 nm, 500-ng aliquots are reverse transcribed.

Animal Study:^{^[1]}

Animal Models
adult C57/BL6 mice (3-6 months old, heterozygous β^KO type) with FE diet (0.2% ferrocene w⁄w)
Dosages
4 mg⁄kg
Administration
i.p.

References

https://pubmed.ncbi.nlm.nih.gov/22404220/
https://pubmed.ncbi.nlm.nih.gov/16424797/

Sellecks Efonidipine Has Been Cited by 1 Publication

Efonidipine Inhibits JNK and NF-κB Pathway to Attenuate Inflammation and Cell Migration Induced by Lipopolysaccharide in Microglial Cells [ Biomol Ther (Seoul), 2022, 30(5):455-464]	PubMed: 35993250

Efonidipine Inhibits JNK and NF-κB Pathway to Attenuate Inflammation and Cell Migration Induced by Lipopolysaccharide in Microglial Cells [ Biomol Ther (Seoul), 2022, 30(5):455-464]

PubMed: 35993250

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.